Patents by Inventor Robert McKean

Robert McKean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MANUFACTURE METHOD FOR AQUEOUS FORMULATION OF MANGANESE-CONTAINING COORDINATION COMPLEX, FORMULATION, AND METHOD OF TREATMENT
    Publication number: 20220227798
    Abstract: A method is provided for manufacturing an aqueous formulation of a manganese-containing coordination complex, by combining a source of the manganese-containing coordination complex with a source of chloride anion in an aqueous solution, and simultaneously with or following combination of the source of chloride anion and the source of manganese-containing coordination complex in the aqueous solution, providing a source of a dianion to the aqueous solution to form the aqueous formulation.
    Type: Application
    Filed: April 7, 2022
    Publication date: July 21, 2022
    Inventors: Robert A. BEARDSLEY, Jeffrey A. SCHOLTEN, James BLACKLEDGE, Dennis P. RILEY, Otto F. SCHALL, Robert MCKEAN
  • Crystalline forms of tiagabine hydrochloride
    Publication number: 20080064727
    Abstract: The present invention provides 16 new crystalline forms of tiagabine hydrochloride.
    Type: Application
    Filed: August 16, 2007
    Publication date: March 13, 2008
    Applicant: Cephalon, Inc.
    Inventors: Scott Childs, Leonard Chyall, Karen Gushurst, R. Haltiwanger, Robert McKean, Donglai Yang
  • Crystalline and amorphous forms of tiagabine
    Publication number: 20080051435
    Abstract: The present invention provides 24 new forms of tiagabine, including 22 new crystalline forms of tiagabine and its salts, an amorphous form of tiagabine free base, and a cocrystal form of tiagabine hydrochloride with 2-furancarboxylic acid. The present invention further provides a process for preparing each of the new tiagabine forms. The present invention further provides a pharmaceutical composition containing at least one of the new tiagabine forms, and a process for the preparation thereof. The present invention further provides a method of treating a disease related to GABA uptake in a mammal, comprising the step of administering to the mammal a therapeutically effective amount of at least one of the new tiagabine forms.
    Type: Application
    Filed: August 16, 2007
    Publication date: February 28, 2008
    Applicant: Cephalon, Inc.
    Inventors: Scott Childs, Karen Gushurst, R. Haltiwanger, Robert McKean, Donglai Yang